Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome
Status:
Enrolling by invitation
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at kidney function and hormonal function in patients
with a history of heart failure and kidney dysfunction, and to see how the use of a new drug,
ANX-042, affects those functions.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)